{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:02:02Z","timestamp":1787169722025,"version":"build-2736575974"},"reference-count":33,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2019,7,9]],"date-time":"2019-07-09T00:00:00Z","timestamp":1562630400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2019,11]]},"abstract":"\n Gemtuzumab ozogamicin (Mylotarg; Pfizer, New York, NY) was the first antibody\u2013drug conjugate to be approved for\n CD<\/jats:styled-content>\n 33\u2010positive acute myeloid leukemia (\n AML<\/jats:styled-content>\n ). However, it was voluntarily withdrawn from the\n US<\/jats:styled-content>\n market due to lack of clinical benefit in the confirmatory phase III trial. In 2012, several investigator cooperative studies using a different dosing regimen showed efficacy, but pharmacokinetic (PK) data were not collected in these trials. Through simulation of expected concentrations for new dosing regimens, PK\/pharmacodynamic modeling was able to support the safety and efficacy of these regimens. Significant exposure\u2013response relationships were found for the attainment of complete remission with and without platelet recovery, attainment of blast\u2010free status, the time course of myelosuppression, several grade\u00a0\u2265\u00a03 hepatic adverse events, and veno\u2010occlusive disease. Gemtuzumab ozogamicin received full approval by the\n US<\/jats:styled-content>\n Food and Drug Administration (FDA) in September 2017 for newly diagnosed and relapsed\n AML<\/jats:styled-content>\n in adult patients and relapsed\n AML<\/jats:styled-content>\n in pediatric patients aged 2\u201317\u00a0years.\n <\/jats:p>","DOI":"10.1002\/cpt.1500","type":"journal-article","created":{"date-parts":[[2019,5,9]],"date-time":"2019-05-09T13:23:41Z","timestamp":1557408221000},"page":"1006-1017","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Pharmacokinetic\/Pharmacodynamic Modeling to Support the Re\u2010approval of Gemtuzumab Ozogamicin"],"prefix":"10.1111","volume":"106","author":[{"given":"Luke K.","family":"Fostvedt","sequence":"first","affiliation":[{"name":"Pfizer Global Product Development La Jolla California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer E.","family":"Hibma","sequence":"additional","affiliation":[{"name":"Pfizer Global Product Development La Jolla California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna C.","family":"Masters","sequence":"additional","affiliation":[{"name":"Pfizer Global Product Development La Jolla California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Vandendries","sequence":"additional","affiliation":[{"name":"Pfizer Global Product Development Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Ruiz\u2010Garcia","sequence":"additional","affiliation":[{"name":"Pfizer Global Product Development La Jolla California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,7,9]]},"reference":[{"key":"e_1_2_10_1_1","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.4049\/jimmunol.141.8.2797","article-title":"Isolation of a cDNA encoding cD33, a differentiation antigen of myeloid progenitor cells","volume":"141","author":"Simmons D.","year":"1988","journal-title":"J. Immun."},{"key":"e_1_2_10_2_1","first-page":"339","article-title":"Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody m195","volume":"3","author":"Tanimoto M.","year":"1989","journal-title":"Leukemia"},{"key":"e_1_2_10_3_1","unstructured":"US Food and Drug Administration.Drug approval package: Mylotarg (gemtuzumab ozogamicin) injection. Application no. 21\u2010174 (2000). Accessed May 17 2018."},{"key":"e_1_2_10_4_1","first-page":"1490","article-title":"Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia","volume":"7","author":"Bross P.F.","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-01-466706"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403350"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1020658028082"},{"key":"e_1_2_10_8_1","first-page":"20","article-title":"Effectiveness of gemtuzumab ozogamicin (mylotarg) treatment: cellular and systemic determinants","volume":"1781","author":"Velden V.H.","year":"2006","journal-title":"Eur. J. Hosp. Pharm. Sci."},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.10.3197"},{"key":"e_1_2_10_10_1","unstructured":"Wyeth Pharmaceuticals Inc. (a subsidiary of Pfizer Inc.).Mylotarg (gemtuzumab ozogamicin; PF\u201005208747) FDA Oncologic Drugs Advisory Committee Briefing Document (BLA 761060). Accessed April 30 2018."},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404434"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60485-1"},{"key":"e_1_2_10_13_1","article-title":"Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updated from the open\u2010label, phase 3 ALFA\u20100701 trial","author":"Lambert J.","year":"2018","journal-title":"Haematologica"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.0060"},{"key":"e_1_2_10_15_1","article-title":"Population pharmacokinetic modeling of gemtuzumab ozogamicin in adult patients with acute myeloid leukemia","author":"Hibma J.E.","year":"2018","journal-title":"Clin. Pharm."},{"key":"e_1_2_10_16_1","article-title":"Population pharmacokinetics of gemtuzumab ozogamicin in pediatric patients with relapsed or refractory acute myeloid leukemia","author":"Masters J.C.","year":"2018","journal-title":"Clin. Pharm."},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.036"},{"key":"e_1_2_10_18_1","unstructured":"US Department of Health and Human Services. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Published: May 28 2009 (v4. 03: June 14 2010). (2016)."},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1023573429626"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.02.140"},{"key":"e_1_2_10_21_1","unstructured":"US Food and Drug Administration.Mylotarg (gemtuzumab ozogamicin for injection) \u2013 FDA (2017)."},{"key":"e_1_2_10_22_1","unstructured":"European Medicines Agency.Mylotarg (gemtuzumab ozogamicin) \u2013 EMA (2018)."},{"key":"e_1_2_10_23_1","volume-title":"Applied Logistic Regression","author":"Hosmer D.W.","year":"2004"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-689976"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.9764"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-09-047399"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.13.3244"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.06.013"},{"key":"e_1_2_10_29_1","unstructured":"University of Birmingham.International randomised phase III clinical trial in children with acute myeloid leukaemia (Myechild01). ClinicalTrials.gov Identifier: NCT02724163 . Accessed January 11 2019."},{"key":"e_1_2_10_30_1","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2014"},{"key":"e_1_2_10_31_1","volume-title":"NONMEM 7.3. 0 Users Guides","author":"Beal S.","year":"1989"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2003.11.003"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-011-1800-z"}],"container-title":["Clinical Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.1500","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpt.1500","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.1500","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T08:27:32Z","timestamp":1699345652000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.1500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,9]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["10.1002\/cpt.1500"],"URL":"https:\/\/doi.org\/10.1002\/cpt.1500","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,9]]},"assertion":[{"value":"2018-11-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}